The major research goal of CTID is to address the unmet need for pediatric-specific immune management by performing state-of-the-art translational and clinical research directed at achieving immune tolerance. Developing strategies to induce immune tolerance is widely recognized as the most pressing goal for bone marrow transplantation (BMT), for diverse autoimmune diseases, and for solid organ transplantation. Immune tolerance would allow widespread use of BMT without the risk of graft versus host disease. It would cure patients with autoimmune diseases without the requirement of complex, life-long medication regimens. And it would allow acceptance of solid organ allografts without the need for lifelong immunosuppression. CTID brings together clinical, translational, and basic research in immunology, genetics and genomics, and molecular cell biology, from institutes across Atlanta including Emory University, Georgia Tech, CHOA and Georgia State University, with the aims to:

  • Develop new treatments for children undergoing organ or bone marrow transplantation and for those with autoimmune disorders.
  • Identify biomarkers and genetic traits associated with these diseases, allowing for improved risk stratification and personalized therapies.
  • Allow Children’s to distinguish itself as a preferred destination for children undergoing transplantation and for those with autoimmune disorders.
  • Support clinical trials designed to evaluate the efficacy of new treatments for immune-mediated disorders.

The vision of CTID is to build a flagship center for translational immunology-based research in children with specific emphasis on immune-mediated childhood diseases, immunodeficiency, transplantation and immune-tolerance-induction.